Prostatic artery embolization (PAE) is a promising non-surgical treatment for lower urinary tract symptoms (LUTS) from benign prostatic hyperplasia (BPH). Clinically shown to reduce BPH symptoms and improve quality of life, PAE has become a viable alternative to surgical procedures, with minimal risk of urinary incontinence or sexual dysfunction such as impotence and retrograde ejaculation. PAE also offers a shorter recovery time compared to surgical options and is performed via the femoral or radial artery.

PHYSICIAN EDUCATION

Learn the minimally invasive technique of Prostatic Artery Embolization (PAE). The ThinkPAE™ education course features numerous cases, didactic presentations including anatomy and patient identification, and hands-on training with simulators utilizing actual PAE cases. The course is led by one of the world’s leading experts in PAE, Dr. Shivank Bhatia.

LEARN MORE

PAE RESOURCE CENTER

The PAE Resource Center includes clinical and educational resources, reimbursement support information, and patient awareness tools for PAE.

Explore PAE Products

From set-up and access to hemostasis and including the first and only embolotherapy product with FDA clearance to treat symptomatic BPH via PAE, Merit offers your tools a la carte, or in several convenient packs.

SET-UP

Prepare and protect your patients efficiently and safely.

RADIAL

FEMORAL

EMBOLOTHERAPY

Treat your patients with predictable outcomes.

Read the press release announcing Merit Medical’s Embosphere® Microspheres Receive FDA 513(f)(2) (de novo) Classification for Prostatic Artery Embolization Indication

PATIENT EDUCATION

Ask4PAE aims to educate patients and their families about PAE as a treatment option for BPH. The program includes Ask4PAE.com as well as patient brochures and other awareness tactics.

      

References

  1. McWilliams, J. P., Kuo, M. D., Rose, S.C., Bagla, S., Caplin, D. M., Cohen, E. I., Faintuch, S., Spies, J. B., Saad, W. E., Nikolic, B. (2014). Society of Interventional Radiology position statement: prostate artery embolization for treatment of benign disease of the prostate. Journal of Vascular and Interventional Radiology, 25: 1349-1351. http://dx.doi.org/10.1016/j.jvir.2014.05.005 http://www.scvir.org/clinical/cpg/SIR_Pos_Statmt_PAE_Benign_dis_Prostate.pdf
  2. Patel, N. D., & Parsons, J. K. (2014). Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian Journal of Urology, 30(2): 170-176. doi: 10.4103/0970-1591.126900
  3. Krista, A. R., Arnold, K. B., Schenk, J. M., Neuhouser, M. L., Weiss, N., Goodman, P., Antvelink, C. M., Penson, D. F., & Thompson, I. M. (2007). Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. The Journal of Urology, 177(4): 1395-1400

For more information please refer to Instructions for Use. Consult product labels and inserts for any indications, contraindications, potential complications, warnings, precautions and directions for use.

Merit Medical
logo

Part

Page

Post